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Introduction
Multipotent mesenchymal stromal cells (MSCs) are widely used in 
tissue engineering and cell therapy [21, 44]. In tissue engineering, 
the ability of  MSCs to differentiate into all tissues of  mesenchy-
mal origin is utilized. MSCs are mainly used for cell therapy due 
to their immune modulatory properties toward T-cells, B-cells, 
NK-cells, macrophages and dendritic cells [4, 49]. MSCs affect T-
cells via soluble immunosuppressive factors, such as transforming 
growth factor beta (TGF-β), hepatocyte growth factor (HGF), 
prostaglandin E synthase (PTGES), prostaglandin E2 (PGE2), 
human leukocyte antigen-G5 (HLA-G5), interleukin 10 (IL10), 
heme-oxygenase-1, indoleamine 2,3-dioxygenase (IDO1) [32], in-
terleukin 6 (IL6) [28], stromal-derived factor 1 (SDF1), intercel-
lular adhesion molecule 1 (ICAM1) [31], vascular cell adhesion 
molecule 1 (VCAM1) [7], matrix metalloproteinases (MMP) [52], 
and others [55]. MSCs engage in direct intercellular interactions 
with lymphocytes via PD-L1/PD-1, CD200/CD200R, FAS-L/
FAS, the costimulatory molecules B7-H4 and toll-like receptors 
[1, 35, 38, 50, 63].
Due to their immunomodulatory properties, MSCs are used for 
the treatment of  acute graft versus host disease (aGVHD), au-
toimmune diseases, inflammatory bowel diseases, and diabetes 
mellitus [29, 60]. However, the use of  MSCs is not always effec-
tive. According to some studies, the immunoregulatory potential 
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Multipotent mesenchymal stromal cells (MSCs) are widely used for cell therapy. Treatment with interferon-γ (IFNγ) in-
creases the immunomodulating properties of  MSCs. When administered intravenously, MSCs interact with lymphocytes. It 
is impossible to follow the fate of  MSCs in the recipient organism. The aim of  this study was to investigate the properties 
of  MSCs after their interaction with lymphocytes in vitro. 
Bone marrow MSCs were co-cultured for 4 days with activated and non-activated lymphocytes. A portion of  the MSCs was 
pretreated with IFNγ.
HLA-DR expression on the MSCs increased when these cells were co-cultured with lymphocytes and after they were treated 
with IFNγ. The activated lymphocytes induced significantly higher HLA-DR expression levels than did IFNγ treatment.
IFNγ increased the viability of  MSCs when these cells were co-cultured with lymphocytes. The immunomodulating proper-
ties of  MSCs were amplified after IFNγ priming and co-cultivation with lymphocytes; therefore, this amplification was not 
dependent on the IFNγ source. IFNγ treatment and lymphocyte interactions induced increases in the relative expression 
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of  MSCs increases after their activation, and these cells become 
more effective in suppressing the immune response. It is expected 
that some molecules can be used for MSC activation. Currently 
the possibility of  activating MSCs with various substances, such 
as IFN-γ, TNF-α, and IL17, is being investigated [10, 41]. It has 
been shown that IFN-γ is needed for the manifestation of  the 
immunosuppressive properties of  MSCs: MSCs do not have an 
effect on the proliferation of  IFN-γ-deficient T-cells [50]. MSCs 
activated by IFN-γ (MSCs-γ) have an increased anti-inflammatory 
effect, and blocking the receptors for IFN-γ leads to a significant 
decrease in immunosuppression [52]. In contrast, pretreatment of  
MSCs with IFN-γ leads to an increase in their immunomodulatory 
properties [42]. However, MSCs-γ became more immunogenic due 
to an increase in the expression of  MHC-I and the appearance of  
MHC-II on the cell surface [11]. After MSCs interact with IFN-γ, 
they began to produce high levels of  IDO1, soluble enzyme that 
cleaves tryptophan, resulting in the accumulation of  kynurenine, 
which has immunosuppressive properties. The efficiency of  the 
IFN-γ treatment depends on its concentration since IFN-γ does 
not change the immunomodulatory properties of  MSCs at a low 
concentration (50 U/ml), whereas it enhances the immunosup-
pressive properties of  MSCs at a high concentration (500 U/ml) 
[32, 40]. The activated MSCs show increased expression levels of  
IL6 and IDO1, leading to more efficient inhibition of  T-cell and 
NK-cell proliferation [20, 36]. MSCs with enhanced IDO1 secre-
tion can more effectively suppress the T-cell-mediated immune 
response by inhibiting proliferation and inducing apoptosis in T-
cells. MSCs-γ boost the number of  regulatory T-cells, which may 
be partly due to increased expression of  PD-L1 [52].Additionally, 
the activated MSCs are characterized by more pronounced sup-
pression of  CD25 expression on CD4+ effector T-cells and the 
suppression of  NK-cells compared to non-activated MSCs. The 
expression levels of  IFN-γ, TNF-α and IL2 decrease in MSCs-γ, 
but the expression level of  PGE2 does not change, which also 
contributes to the immunomodulatory properties of  these cells. 
MSCs do not express the co-stimulatory molecules CD80, CD83, 
and CD86 even under the influence of  IFN-γ [53], and CD40 ex-
pression data are contradictory [8, 53]. After MSCs are primed by 
IFN-γ, they begin to express MHC II molecules that promote T-
cell activation and cytotoxic reactions. Clinical use of  MSCs-γ can 
lead to complications including acute immune responses. The ap-
plication of  MSCs-γ in animal models has been effective. Crohn’s 
disease has been modeled in mice that have been administered 
dextran coupled with trinitrobenzene sulfonate. Administration 
of  human MSCs-γ in these mice led to better survival, and the 
mice gained weight as the severe symptoms of  colitis subsided 
[17]. Thus, the ability to increase the therapeutic efficacy of  MSCs 
has been illustrated. 
MSCs have been well characterized in vitro. However, what hap-
pens to MSCs after intravenous injection remains unclear. It is 
known that 2 weeks after infusion, MSCs could not be detected 
in the recipient organism [2]. Typically, MSCs are administered 
intravenously, and their interaction with lymphocytes occurs in 
the blood and tissues. MSCs express multiple adhesion molecules 
on their surface, which allows them to interact with lymphocytes 
[5]. Lymphocytes secrete cytokines that act on the MSCs [22]. As 
a result, properties of  the MSCs, such as their ability to modulate 
the immune response and their trophic function, can change. The 
immune system of  the recipient thus gains the ability to recognize 
these foreign MSCs, and the MSCs lose their immune privilege 
[3].
The aim of  this study was to investigate the changes in the main 
properties of  MSCs after these cells interact with allogeneic lym-
phocytes. The MSCs were co-cultured with lymphocytes for 4 
days, and their basic properties were analyzed over time. The in-
teraction of  MSCs with lymphocytes led to the appearance of  
HLA-DR expression on the surface of  MSCs. CD90 expression 
was reduced over time, and IDO1, CFH, PTGES, IL6, and CSF1 
expression was elevated. These changes may affect the duration 
of  exogenous MSC survival in the recipient organism.
Materials And Methods
MSCs
MSCs were isolated from the bone marrow of  13 donors (7 males 
and 6 females), ranging in age from 22 to 62 years (median: 27 
years). After informed consent was obtained, samples were col-
lected during the aspiration of  hematopoietic stem cells for al-
logeneic transplantation at the Department of  Bone Marrow 
Transplantation. The protocol was approved by the local medical 
ethics committee.
The MSCs were derived from 5-10 ml of  donor bone marrow. For 
the separation of  mononuclear cells, the bone marrow was mixed 
with an equal volume of  alpha-МЕМ (ICN) containing 0.2% 
methylcellulose (1500 cP, Sigma-Aldrich). After 40 min, most 
of  the erythrocytes and granulocytes had precipitated, while the 
mononuclear cells remained in suspension. The suspended (up-
per) fraction was aspirated and centrifuged for 10 min at 450×g.
The cells from the sediment were re-suspended in a standard cul-
ture medium that was composed of  alpha-MEM supplemented 
with 10% fetal bovine serum (Hy Clone), 2 mМ L-glutamine 
(ICN), 100 U/ml penicillin (Ferein) and 50 microg/ml strepto-
mycin (Ferein). The cells (3×106) were cultured in T25 culture 
flasks (Corning-Costar). When a confluent monolayer of  cells 
had formed, the cells were washed with 0.02% EDTA (ICN) 
in a physiological solution (Sigma-Aldrich) and then trypsinized 
(ICN). The cells were seeded at 4×103 cells per cm2 of  flask 
growth area. The cultures were maintained at 37°C in 5% CO2. 
The number of  harvested cells was counted directly; cell viability 
was checked by trypan blue dye exclusion staining.
All MSCs were immunophenotyped with following markers: 
CD105, CD73, CD45, CD34, CD14, HLA-DR using stand-
ard protocols. Antibodies were purchased at BD Pharmingen 
(CD105, CD59, CD73, CD90, CD31, CD34 and CD14), Sigma 
(CD45, FSP) and DAKO (HLA-DR). All MSCs were in accord-
ance with MSCs minimal definition criteria [16].
Human interferon gamma (IFN-γ) (Ingaron, Farmaclone) was 
dissolved in alpha-МЕМ and added at a concentration of  500 U/
ml to the MSC culture for 4 hours. Then, the culture medium was 
changed [40].
RNA
Total RNA was extracted from the MSCs at passage 1 by the 
standard method [13], and cDNA was synthesized using a mixture 
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of  random hexamers and oligo (dT) primers. Gene expression 
levels were quantified by real-time quantitative PCR using hydrol-
ysis probes (TaqMan) and an ABI Prism 7500 (Life Technologies). 
Gene-specific primers were designed by the authors and synthe-
sized by Syntol R&D. All primers and probe sequences are pro-
vided in Supplement 1. The relative expression levels (RELs) of  
the genes were determined by normalizing the expression of  each 
target gene to the levels of  βACTIN and GAPDH and calculated 
using the ΔΔCt method [48] for each MSC sample.
Immunophenotyping
The expression of  the MHC antigens on the MSC level was de-
termined by flow cytometry. After the MSCs were removed from 
the bottom of  the flask, they were washed twice with Cell WASH 
(BD Biosciences, USA), and then 2×104 cells were incubated for 
20 min in the dark with one of  the following monoclonal anti-
bodies: anti-CD90 labeled with PE (BD Pharmingen, USA), anti-
CD54 labeled with APC (BD Biosciences, USA) or anti-HLA-DR 
labeled with APC (BioLegend, USA). Analyses were performed 
using a FACS Canto II flow cytometer (BD Biosciences, USA), 
and the data were analyzed using FACS Diva software (BD Bio-
sciences, USA).
The MSC population was first determined by forward and side 
scattering parameters and then isolated based on the expression 
of  CD90. For this cell population, the mean fluorescence inten-
sities (MFIs) for the channels PE (CD90) and APC (HLA-DR) 
were evaluated.
Lymphocytes preparation
For the analysis of  interactions between MSCs and lymphocytes, 
lymphocytes from healthy donors were separated using Lym-
phoprep solution at a density of  1.077 g/cm3 (MP Biomedicals). 
The obtained mononuclear cell fraction was washed 3 times with 
RPMI-1640 medium without serum. All the experiments were 
performed on lymphocytes from the same donor. In some experi-
ments, lymphocytes derived from MSCs from the donor’s periph-
eral blood were used in addition to the standard. Lymphocytes 
and MSCs were co-cultured for 4 days at 37°C and 5% CO2. As 
controls, lymphocytes cultured without MSCs were used.
Schedule of  experiments
MSCs at 2-3 passages were seeded at a density of  105 cells per T25 
flask, and a day later, some of  the flasks were treated with IFN-γ 
for 4 hours (MSCs-γ). Then, the flasks were washed and 106 lym-
phocytes suspended in RPMI-1640 medium supplemented with 
10% FBS were added. In some experiments, the lymphocytes 
were activated with 5 mg/ml phytohemagglutinin (PHA-lympho-
cytes). MSCs and MSCs-γ cultured in RPMI-1640 medium with-
out lymphocytes were used as controls. Flasks were kept for 4 
days after the addition of  the lymphocytes at 37 °C and 5% CO2.
After the 1st, 2nd, 3rd and 4th days, the lymphocytes were washed 
from the MSC layers. The MSCs were removed by trypsinization, 
and the number of  viable cells was determined by the dye exclu-
sion method (trypan blue). For each MSC culture, flow cytometric 
analysis was performed as described above.
Statistics
The data are presented as the means ± SEM. The data were ana-
lyzed using Student’s t-test (considered reliable at p<0.05).
Results And Discussion
After intravenous administration, MSCs interact with lympho-
cytes in the peripheral blood and various tissues. An attempt to 
study the dynamics of  changes in the characteristics of  MSCs fol-
lowing their interaction with lymphocytes in vitro was made. Ac-
tivated and non-activated allogeneic lymphocytes were explanted 
onto MSC cultures at a ratio of  approximately 10:1 with RPMI-
1640 medium with 10% FBS. This ratio of  lymphocytes to MSCs 
adequately reflects the situation after intravenous administration 
of  MSCs to prevent or treat a GVHD after the transplantation 
of  allogeneic hematopoietic stem cells [27, 47]. Some samples of  
MSCs were pretreated with IFN-γ for 4 hours. The scheme of  the 
experiments is shown in Figure 1.
MSCs are considered immune privileged because they do not ex-
press HLA-DR on their surface in vitro.
Figure 1. Scheme of  Experiments.
+ Lymphocytes + Lymphocytes + PHA-lymphocytes + PHA-lymphocytes
MSCs analysis on 1, 2, 3 and 4 days of  co-cultivation
Control MSCs MSCs MSCs-γ MSCs MSCs-γ
MSCs were seeded to 4 flasks for each variant. Lymphocytes or PHA-Lymphocytes were added one day after culture establishment. 
Then each day 1 flask per variant was analyzed.
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HLA-DR expression of  on the surface of  MSCs after these 
cells interact with lymphocytes
In the MSCs co-cultured with both autologous and allogeneic 
lymphocytes, the level of  HLA-DR surface expression gradu-
ally increased by 1.4 times on day 1 and then by 1.7, 1.7 and 2 
times (p=0.03) on days 2, 3 and 4, respectively (Figure 2A, B). It is 
known that an increase in HLA-DR expression on MSCs can oc-
cur after their treatment with immunomodulatory agents without 
T-cell activation [14].
When MSCs were co-cultured with PHA-lymphocytes, the level 
of  HLA-DR expression on these cells increased more signifi-
cantly than when they were co-cultured with non-activated lym-
phocytes, with increases of  2.8 times after the 1st day and then 
9.1, 12.2 and 12.3 times after the 2nd, 3rd, and 4th day, respec-
tively (p<0.05 in all cases)(Figure 2C). IFN-γ priming caused an 
increase in the level of  HLA-DR expression on MSCs-γ. This 
expression of  HLA-DR on the MSCs-γ was more pronounced 
than in the presence of  non-activated lymphocytes. HLA-DR 
expression on the MSCs-γ without lymphocyte interaction in-
creased 2.2 times after 1st day (p=0.009) and 4.7 (p=0.001) and 
6.3 (p=0.0004) and 8.2 (p=0.001) times on each subsequent day 
(Figure 2D). The MSCs-γ co-cultured with lymphocytes showed 
a much greater increase in HLA-DR expression than MSCs that 
interacted with lymphocytes: an increase of  2.4 times after the 1st 
day and increases of  5.0, 5.5 and 4.6 times after the 2nd, 3rd, and 
4th day, respectively (p<0.05 in all cases) (Figure 2E). However, 
this increase was not as pronounced as after the MSCs-γ inter-
acted with PHA-lymphocytes (Figure 2F). It was found that af-
ter 4 days of  co-culturing of  MSCs-γ with lymphocytes, the level 
of  HLA-DR expression was significantly lower (p=0.05) than in 
the MSCs-γ without lymphocytes. Co-culturing of  MSCs-γ with 
PHA-lymphocytes resulted in HLA-DR expression increases of  
3.6, 11.9, 13.7 and 12.4 times during each subsequent day, and this 
result did not differ from that seen in the MSCs (Figure 2F). Pre-
viously, it has been shown that MSCs-γ have a phenotype similar 
to that of  MSCs (expression of  markers such as CD45, CD11b, 
CD44 and CD29 [40]), which is consistent with our observation.
Thus, after intravenous administration of  MSCs or MSCs-γ and 
the interaction of  these cells with lymphocytes, the HLA-DR ex-
pression level would most likely increase in the same manner, i.e., 
the activation of  MSCs with IFN-γ will not significantly affect the 
immune response in vivo.
The study of  MSC growth parameters in the presence of  lympho-
cytes showed a significant increase in the proportion of  dead cells. 
It is known that foreign MSCs are not detected in the recipient 2 
weeks after intravenous administration [2, 19]. The data obtained 
can partly explain these observations.
MSC growth parameters
When MSCs were cultured in αMEM supplemented with 10% 
FBS, their numbers increased 2-3 times within 3-4 days after 
passaging [56]. In these experiments, the MSCs were cultured in 
RPMI-1640 with 10% FBS, which resulted in a reduction in the 
proliferation of  these cells. Even in the control samples, adequate 
increases in the cell number were not observed. Cellular produc-
tion did not change significantly in MSCs-γ during co-culture with 
lymphocytes (Table 1). When MSCs were co-cultured with PHA-
lymphocytes, their cell number decreased regardless of  IFN-γ 
pretreatment; however, these changes were not significant.
The proportion of  living cells in the cultures varied, and pretreat-
Figure 2. Dynamics of  HLA-DR Expression on MSCs.
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ment with IFN-γ led to an insignificant decrease in the proportion 
of  viable cells. A significant decrease in the proportion of  viable 
MSCs was revealed in co-cultures with PHA-lymphocytes (Figure 
3.) after 4 days, while such an effect was not observed in cultures 
pretreated with IFN-γ. This finding may indicate the sensitization 
of  MSCs-γ to factors secreted by the activated lymphocytes.
The differentiation potential of  MSCs can change after injection. 
It is known that the expression of  CD90 (a MSC markers)de-
creases during the differentiation of  these cells [34, 51]. Further-
more, Thy-1 (CD90) glycoproteins are involved in cell-cell inter-
actions. The study of  CD90 expression on the MSCs co-cultured 
with lymphocytes showed a decrease in its expression levels.
CD90 expression on MSCs
The CD90 expression levels on MSCs and MSCs-γ did not change 
during culture. On the MSCs and MSCs-γ co-cultured with lym-
phocytes, the CD90 expression level gradually decreased: after 2 
days, it differed from the original, and by the 4th day, it decreased 
by 1.5 times (Figure 4A, B, C). Co-culture of  MSCs and MSCs-γ 
with PHA-lymphocytes resulted in a more significant reduction in 
the CD90 expression level (1.3, 1.2, 1.5, 2.3 and 1.1, 1.0, 1.6, and 
2.1 times after the 1st, 2nd, 3rd and 4th day, respectively) (Figure 4D, 
E). The findings indicate that the interaction with lymphocytes 
lead to MSC differentiation.
To test this hypothesis, the expression of  the standard differen-
tiation markers of  MSCs was investigated. The genes involved 
in osteogenic differentiation (SPP1 and BGLAP), adipogenic dif-
ferentiation (PPARG) and chondrogenic differentiation (SOX9) 
were analyzed. The relative expression levels (RELs) of  SOX9 
and BGLAP did not change in any of  the experiments. The REL 
of  SPP1 increased by 2 times in the MSCs-γ co-cultured with lym-
phocytes (p=0.04). 
PPAR-γ is one of  the key regulators of  adipogenesis. In the ab-
sence of  PPAR-γ, there is no formation of  normal adipocytes 
[25]. The REL of  PPARG did not change in the MSCs during 
culture. In the MSCs-γ, the REL of  PPARG increased more than 
2 times (1.1 ± 0.4 on the first day compared to 2.7 ± 0.8 on day 4, 
p=0.04). It is important to note that one of  the main functions of  
PPAR-γ, as a member of  the nuclear receptor family, is the regu-
lation of  gene expression at the mRNA level. PPAR-γ regulates 
chemokine activation after treatment with IFN-γ [54].
After 4 days of  MSCs and MSCs-γ co-culture with lymphocytes, 
the REL of  PPARG significantly decreased from 1.4 ± 0.4 to 0.5 
± 0.1 (p=0.04) and from 2.7 ± 0.8 to 0.9 ± 0.3 (p=0.02), respec-
tively. Opposite results were obtained by Wu et al., [62]. When 
the MSCs were co-cultured with PHA-lymphocytes in this study, 
the REL of  PPARG significantly increased. The analysis in that 
paper was carried out one day after the beginning of  incubation. 
In our study, no significant differences were detected on the first 
day. A significant increase in the REL of  PPARG was detected 
only in the IFN-γ-primed MSCs without lymphocytes after 4 days 
of  incubation. Perhaps these contrasting results are due to the 
significant differences in the ratios of  lymphocytes and MSCs 
in these studies. It is known that PPAR-γ is expressed mainly in 
adipose tissue cells, but it is also expressed in lymphocytes, mac-
rophages, fibroblasts and chondrocytes [37]. In addition, the in-
crease in PPARG expression could be attributed to an additive 
effect, which we did not observe in our experiments.
Thus, the interaction of  MSCs with lymphocytes have different 
influences on the differentiation potential of  MSCs. It is possi-
ble that IFN-γ priming changes the osteogenic and adipogenic 
differentiation abilities of  MSCs but not their chondrogenic dif-
ferentiation ability.
Reduced CD90 expression affects the intercellular interactions 
and adhesion of  activated T-cells [26, 46]. This interaction is sup-
ported by integrins. In addition to CD90, the cell adhesion mol-
ecule ICAM-1 is important in the study of  MSC interactions with 
lymphocytes. ICAM-1 is a ligand of  the LFA-1 integrin receptor, 
which is detectable on leukocytes and whose activation is neces-
sary for the transition of  lymphocytes into the tissue [64].
ICAM-1
ICAM-1 is present at low concentrations on the membranes of  
leukocytes and endothelial cells [59]. According to our immuno-
fluorescence studies, 76.4 ± 1.3% of  the MSCs expressed ICAM-
1 (CD54). When the MSCs were co-cultured with lymphocytes 
Figure 3. Alterations in the Proportion of  Viable Cells in Culture.
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
1 2 3 4
days in culture
%
 o
f 
vi
ab
le
 c
el
ls MSCs
MSCs-γ
MSCs-lymphocytes
MSCs-γ+lymphocytes
MSCs-PHA+lymphocytes
MSCs-γ+PHA+lymphocytes
p=0.02
Kapranov NM, Davydova YO, Galtseva IV, Bakshinskayte MV, Drize NJ, et al., (2017) Alterations of  Multipotent Mesenchymal Stromal Cells Induced by Interaction with Allogeneic Lymphocytes 
In Vitro. Int J Stem Cell Res Transplant. 5(2), 277-286. 282
  OPEN ACCESS                                                                                                                                                                                    http://scidoc.org/IJST.php 
and PHA-lymphocytes, ICAM-1 began to be expressed on all 
MSCs, whereas the REL of  ICAM-1, as determined by RT-PCR, 
increased 8 times and 35.1 times, respectively (Figure 5.). It is 
known that MSC stimulation by cytokines, including IL-1 and 
TNF-α, sharply increases ICAM-1 expression on the cytoplasmic 
membrane [6, 15]. After MSC pretreatment with IFN-γ, the pro-
portion of  cells expressing ICAM-1 was significantly increased 
(p=0.008) by up to 89.8 ± 1.8%. Gene expression analysis re-
vealed that the REL of  ICAM-1 in the MSCs-γ increased signifi-
cantly by 3.6 times,14.6 times when co-cultured with lymphocytes 
and 49.8 times with PHA-lymphocytes (Figure 5.) after 4 days of  
co-culturing. It is known that co-culture of  MSCs with neutro-
phils also increases ICAM-1 expression levels by up to 100 times 
compared to controls [23]. Increased ICAM-1 expression after 
treatment with IFN-γ is in agreement with the data from other 
researchers [45].
Increased ICAM-1 expression enhances cell-to-cell interactions. 
MSCs are the elements of  the hematopoietic stromal microen-
vironment that regulate the process of  hematopoiesis locally by 
cell-to-cell interactions and distantly through secreted soluble 
factors [18]. MSCs administered intravenously effectively par-
ticipate in immunomodulation due to cell-cell contacts, which 
are enhanced by increasing the expression of  ICAM-1, and due 
toparacrine functions and microvesicles [9, 55]. 
The immunomodulatory agents of  MSCs include IDO1, PTGES, 
and CFH, as well as other chemokines and cytokines [24].
Interaction with lymphocytes and pretreatment with IFN-γ sig-
nificantly increase the expression of  IDO1 in MSCs.
IDO1 expression
The REL of  IDO1 increased dramatically in MSCs after both 
IFN-γ pretreatment and lymphocyte co-culture (Figure 6A). 
When the MSCs were co-cultured with lymphocytes, the REL of  
IDO1 increased by 250 times, but by the 4th day of  culture, it 
gradually decreased by 4 times (Figure 6C). The REL of  IDO1 
in MSCs-γ increased by 350 times compared with control MSCs; 
however, on the 4th day of  culture, there was only a 10-fold in-
crease in the REL of  IDO1 compared to controls (Figure 6B). 
The addition of  lymphocytes to the MSCs-γ increased the REL 
of  IDO1 by 750 times, and it decreased by only 2 times after 4 
days of  co-culture (Figure 6D). When MSCs and MSCs-γ were 
co-cultured with PHA-lymphocytes, the REL of  IDO1 increased 
by 2000-4000 times, and there was no reduction in this level dur-
ing culture (Figure 6E, F).
Co-culture of  MSCs with lymphocytes and their priming by 
IFN-γ significantly increased the REL of  IDO1. When lympho-
cytes were co-cultured with MSCs, they begin to express high lev-
els of  IFN-γ. The expression of  IFN-γ by lymphocytes greatly 
increases after their activation with PHA [58]. The dual effect of  
IFN-γ and lymphocytes induced a similar dramatic increase in the 
REL of  IDO1. These data correlate with the results obtained by 
Zhang and co-authors [65]. In that work, the escalation of  IFN-γ 
doses increased the expression of  IDO1 at both the RNA and 
protein levels.
Figure 4. Dynamics of  CD90 expression on MSCs.
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During culture, the REL of  IDO1 decreased in all variants of  
experiments. However, if  the effect was strong enough (IFN-γ 
primed cells or PHA-lymphocytes), on the 4th day, the REL of  
IDO1 in MSCs remained very high, i.e., 450-2000 times higher 
than in control MSCs. Thus, in the case of  cell therapy, it may be 
most effective to administer IFN-γ-activated MSCs on the first 
day after priming. The effect of  the exposure to IFN-γ in vitro 
explains the enhanced therapeutic activity of  MSCs in the model 
of  colitis [28], as well as their better activity after freezing and 
thawing [12]. 
It is known that MSCs secrete a complement inhibitor - comple-
ment factor H (CFH) [60, 61]. CFH inhibits complement activa-
tion by limiting the activity of  C3 and C5 convertases and by con-
tributing to the inactivation of  C3b and C4b. MSCs constitutively 
produce CFH, and this production is increased under the action 
of  IFN-γ and TNF-α but not of  IL-6 [57]. The REL of  CFH 
also increased in MSCs-γ and MSCs co-cultured with lymphocytes 
(Figure 7A). 
No significant changes in the REL of  CFH in the MSCs were 
observed during culture. In both MSCs-γ and MSCs co-cultured 
with lymphocytes, the REL of  CFH increased by 2-2.5 times (sig-
nificant differences were detected only one day after IFN-γ treat-
ment and when co-cultured with lymphocytes; p=0.01 and 0.001, 
respectively). The addition of  PHA-lymphocytes increased the 
Figure 5. Alterations in REL of  ICAM1 in MSCs.
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expression of  this gene by 3-4 times in comparison with control 
MSCs.
PTGES expression
The REL of  PTGES did not change in the MSCs-γ (Figure 7B). 
When MSCs were co-cultured with lymphocytes, the REL of  
PTGES increased by 2 times but not significantly. Co-culture of  
MSCs-γ with lymphocytes increased the expression of  this gene 
by 4 times (p=0.003). Co-culture of  MSCs and MSCs-γ with 
PHA-lymphocytes increased the REL of  PTGES by 3.7 and 4.2 
times, respectively (both p=0.03).
The immunomodulatory properties of  MSCs can be enhanced 
by various cytokines secreted by activated lymphocytes. The ef-
fects of  these molecules on MSCs depends on the cytokine type 
and their concentrations [61]. At the functional level, it has been 
shown that the treatment of  MSCs with IFN-γ protects these cells 
from NK-cells by enhancing the synthesis of  prostaglandin E2 
[36]. Both priming with IFN-γ [43] and interacting with lympho-
cytes [30] induce PTGES expression in MSCs.
IL-6 expression
It has been shown that MSCs produce IL-6, which promotes the 
inhibition of  monocyte differentiation into antigen-presenting 
cells [33]. It is known that IFN-γ treatment of  MSCs for 4 days 
leads to an increase in the IL-6 expression level [66]. In our exper-
iments, MSC priming with IFN-γ did not affect the REL of  IL-6 
(Figure 7C). When MSCs and MSCs-γ were co-cultured with lym-
phocytes, the REL of  IL-6 increased by almost 20 times (p=0.015 
and p=0.0005, respectively). During culture, the REL of  IL-6 in 
MSCs decreased by 2 times. However, in the case of  MSCs-γ, the 
REL of  IL-6 did not decrease. Co-culture of  MSCs and MSCs-γ 
with PHA-lymphocytes led to increases in the REL of  IL-6 of  25 
times, and in both cases, the REL was reduced by half  by the 4th 
day of  co-culture.
Thus, the treatment of  MSCs with IFN-γ resulted in a stable REL 
of  IL-6 without any decrease after these cells interacted with lym-
phocytes. This fact should be taken into the account for improv-
ing the immunomodulatory functions of  MSCs injected into an 
organism.
CSF1 expression
The REL of  CSF1 increased in the MSCs-γ by 2 times (p=0.05)
(Figure 7D). Incubation of  MSCs with lymphocytes increased the 
REL of  CSF1 by 4 times (p=0.02). Co-culture of  MSCs-γ with 
lymphocytes increased the REL of  CSF1 by 7 times (p=0.004). 
When MSCs and MSCs-γ were co-cultured with PHA-lympho-
cytes, the REL of  CSF1 increased by 10 times (p=0.04 and 0.05, 
respectively) and decreased after 3 days by 2 times compared to 
the first and second days of  co-culture (p=0.0009). In all other 
cases, the increased REL of  this factor did not depend on the 
duration of  co-culture.
In summary, the data suggest that IFN-γ stabilized and activated 
the expression of  CSF1, which is involved in the immunomodula-
tory properties of  MSCs.
Figure 7. Alterations in REL of  CFH, PTGES, IL-6 and CSF1 in MSCs.
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The data clearly identified significant changes in MSCs after lym-
phocyte interaction and following IFN-γ treatment.
It is assumed that the immunomodulatory properties of  MSCs 
are not constitutive and can be induced by inflammatory factors 
secreted by activated lymphocytes. The immunomodulatory effect 
of  MSCs depends on the type and concentration of  cytokines, in-
dicating the plasticity of  these cells [61]. This study simulates the 
interaction of  MSCs with lymphocytes that possibly occurs in vivo.
When MSCs interact with activated lymphocytes, HLA-DR be-
gins to be expressed on their surface more extensively than after 
IFN-γ priming. This fact is very important for the selection of  
the source of  MSCs for the treatment of  autoimmune diseases 
and a GVHD. The preference of  autologous MSCs is obvious 
in the first case, and MSCs obtained from hematopoietic stem 
cells of  the donor should be used in the second case. According 
to this study, the immune privilege of  MSCs disappears within 2 
days of  their interaction with the recipient’s lymphocytes. Moreo-
ver, the data suggest rapid elimination of  MSCs from the organ-
ism, as confirmed by the inability to detect MSCs 2 weeks after 
their administration [2, 19]. IFN-γ stabilized the MSCs, and the 
proportion of  viable cells was significantly higher in MSCs-γ af-
ter 4 days of  co-culture with lymphocytes. Perhaps the effect of  
IFN-γ on the stabilization of  MSCs also helps to maintain their 
immunomodulatory properties after cryopreservation [12]. The 
changes in the properties of  MSCs did not strongly depend on 
the source of  IFN-γ (exogenous or IFN-γ secreted by lympho-
cytes). The level of  ICAM-1 expression on the MSCs increased, 
which led to elevation of  their adhesive properties, and the de-
crease in CD90 expression may indicate a change in the differen-
tiation state of  the cells in the population. Both the IFN-γ treat-
ment and lymphocyte interaction induced increases in the RELs 
of  factors involved in immunomodulation (IDO1, CFH, PTGES, 
IL6, and CSF1). However, we have not obtained any evidence to 
support the hypothesis that the treatment of  MSCs with IFN-γ 
enhances their immunomodulatory properties during intravenous 
administration. Interaction with the recipient’s lymphocytes caus-
es the same changes in the main properties of  MSCs as IFN-γ 
priming. However, the treatment with IFN-γ stabilizes the MSCs 
while maintaining their viability. 
Based on the results of  this work, the following are recommended 
for cell-based therapies: 1. MSCs obtained from the hematopoi-
etic cells donor or autologous 2. short-term pretreatment of  the 
MSCs with IFN-γ prior to their use in cell-based therapies for 
immunomodulation.
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